To evaluate the association of each ctDNA-based signatures with patient’s outcome, we analyzed baseline pre-treatment plasma samples from 124 patients with advanced HR+/HER2- breast cancer treated with endocrine therapy and a CDK4/6 inhibitor (CDK-Validation-1 cohort). This evidence concerns the gene ERBB2 and breast cancer.